<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019097</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064244</org_study_id>
    <secondary_id>NCI-97-C-0033B</secondary_id>
    <secondary_id>NCI-T94-0094N</secondary_id>
    <secondary_id>CRB-9409</secondary_id>
    <nct_id>NCT00019097</nct_id>
    <nct_alias>NCT00001562</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune&#xD;
      response and kill their tumor cells. Peripheral stem cell transplantation may be able to&#xD;
      replace immune cells that were destroyed by chemotherapy used to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation&#xD;
      plus vaccine therapy and chemotherapy in treating patients who have multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether autologous myeloma-derived immunoglobulin idiotype&#xD;
      conjugated to keyhole limpet hemocyanin plus sargramostim (GM-CSF) can induce cellular and&#xD;
      humoral immunity against the unique idiotype expressed on the surface of myeloma cells in&#xD;
      patients with multiple myeloma undergoing second autologous peripheral blood stem cell&#xD;
      transplantation.&#xD;
&#xD;
      II. Determine the clinical efficacy and safety of this regimen in these patients.&#xD;
&#xD;
      PROTOCOL OUTLINE: Within 6 months after the first autologous peripheral blood stem cell&#xD;
      transplantation (APBSCT), patients receive melphalan IV over 30 minutes on day -2 and the&#xD;
      second APBSCT on day 0. Sargramostim (GM-CSF) is administered subcutaneously (SC) beginning&#xD;
      on day 1 and continuing until blood counts recover. Patients are also assigned to 1 of 3&#xD;
      vaccination groups.&#xD;
&#xD;
      Group 1: Patients receive autologous myeloma-derived immunoglobulin idiotype conjugated to&#xD;
      keyhole limpet hemocyanin (Id-KLH) SC on day 1 and GM-CSF SC on days 1-4 of months 2, 3, and&#xD;
      5 after the second APBSCT for a total of 3 vaccinations.&#xD;
&#xD;
      Group 2: Patients receive Id-KLH SC on day 1 and GM-CSF SC on days 1-4 of months 2, 3, 4, 5,&#xD;
      6, and 8 after the second APBSCT for a total of 6 vaccinations.&#xD;
&#xD;
      Group 3: Patients receive Id-KLH SC on day 1 and GM-CSF SC on days 1-4 of weeks -8, -6, and&#xD;
      -2 before and months 2, 3, and 5 after the second APBSCT for a total of 6 vaccinations.&#xD;
&#xD;
      Patients are followed within 3 months and then every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A maximum of 60 patients (20 per treatment group) will be accrued for this study within 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1995</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>Refractory Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>keyhole limpet hemocyanin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Immunoglobulin G or immunoglobulin A (IgA) multiple myeloma Low&#xD;
        or intermediate risk disease based on the following criteria: Cytogenetics: no&#xD;
        translocations, 11q, or -13/13q- Beta-2 microglobulin less than 2.5 mg/L before the first&#xD;
        autologous peripheral blood stem cell transplantation (APBSCT) M-protein concentration in&#xD;
        harvested plasma greater than 50% of total immunoglobulin of corresponding isotype&#xD;
        (M-protein must be able to be purified by protein A- or anti-IgA-sepharose) Patients&#xD;
        achieving partial or complete response after the first APBSCT eligible --Prior/Concurrent&#xD;
        Therapy-- Biologic therapy: See Disease Characteristics No prior APBSCT with CD34 selected&#xD;
        stem cells Chemotherapy: Not specified Endocrine therapy: Steroids must be discontinued at&#xD;
        least 4 weeks prior to vaccination No concurrent steroids Radiotherapy: Not specified&#xD;
        Surgery: Not specified Other: Any prior therapy must be completed at least 8 weeks prior to&#xD;
        second APBSCT Recovered from the toxic effects of prior therapy No concurrent aspirin or&#xD;
        nonsteroidal antiinflammatory drugs --Patient Characteristics-- Age: 18 and over&#xD;
        Performance status: Karnofsky 70-100% Life expectancy: More than 8 weeks Hepatic: Bilirubin&#xD;
        less than 2.0 mg/dL and not rising for at least 2-4 weeks before transplantation SGOT no&#xD;
        greater than 4 times upper limit of normal and not rising for at least 2-4 weeks before&#xD;
        transplantation Renal: Creatinine less than 2 times normal and not rising for at least 2-4&#xD;
        weeks before transplantation OR Creatinine clearance greater than 40 mL/min Cardiovascular:&#xD;
        LVEF greater than 50% by MUGA scan Pulmonary: DLCO greater than 50% predicted Other: No&#xD;
        other medical condition that would increase risk of transplantation HIV negative Not&#xD;
        pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Larry W. Kwak</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicine Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>body system/site cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>hematopoietic/lymphoid cancer</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>multiple myeloma and other plasma cell neoplasms</keyword>
  <keyword>plasma cell neoplasm</keyword>
  <keyword>refractory plasma cell neoplasm</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage, plasma cell neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

